A B S T R A C T The factors important in host defense against group B streptococci are not well understood. The role ofantibody and complement in the prevention of serious infection by these organisms is not known because, to date, a reliable measure of functional opsonic activity has not been developed. Recently, it has been shown that neutrophils produce a chemiluminescence after ingestion of particulate matter, and that this event can be detected and quantitated in a liquid scintillation system. We have adapted the chemiluminescence procedure to examine rabbit hyperimmune and human serum for the presence of group B streptococcal opsonins. Group B streptococci of types Ia, II, and III that were opsonized in homologous but not heterologous type serum produced a peak in chemiluminescence when added to normal human neutrophils. Such activity was correlated, in each instance, with ingestion of bacteria by neutrophils and deposition of immunoglobulin and C3 on the bacterial surface as detected by indirect immunofluorescence.
INTRODUCTION
In recent years streptococci of Lancefield's group B have become a leading cause of serious infections in infancy. Although a number of clinical and epidemiological reports on infection due to these organisms have appeared in the literature (1) (2) (3) (4) (5) (6) (7) (8) , there is little definitive information on the factors important in the host defense mechanism against the strains of this group. Lancefield and co-workers have shown that rabbit hyperimmune group B streptococcal antiserum will passively protect mice injected with virulent strains of group B streptococci (9) (10) . Since such antiserum does not appear to possess direct bactericidal activity, mouse protection most likely results from opsonic antibodies present in the serum. The role of specific and nonspecific opsonins in the prevention of infection due to group B streptococci has not been adequately investigated, however, because of the lack of a reliable method for detecting and quantitating functional opsonins for these organisms.
Allen and associates (11) (12) (13) (14) (15) have reported that human neutrophils emit a chemiluminescence after phagocytosis of opsonized bacteria. The chemiluminescence, which can be detected and quantitated in a liquid scintillation counter, appears to result from decay to the ground state of electronically excited carbonyl groups thought to be generated during singlet oxygen mediated oxidation of phagocytized substrate. In the studies reported here, we have adapted the chemiluminescence procedure to examine rabbit hyperimmune and human serum for the presence of group B (wild strains) were cultured at 37°C in 50 ml of Todd-Hewitt (Difco Laboratories, Detroit, Mich.) broth for 20 h. In selected experiments, the strains were grown in the buffered, glucose-enriched broth described by Baker et al. (16) , and harvesting was carried out after 4 h of incubation during log phase growth. The organisms in the broth cultures were sedimented by centrifugation, the supernatant broth was removed and discarded, and the concentrated organisms were washed three times in sterile phosphate-buffered saline (PBS)l (4,500 ml distilled water, 5.2 g Na2HPO4, 0.9 g KCl, 0.9 g KH2PO4, 36 g NaCI). Standard suspensions of organisms of each reference type were prepared by diluting the concentrated, washed organisms in sterile PBS to an optical density (OD) of 0.9 at a wave length of 620 nm (Spectronic 20, Bausch & Lomb Inc., Rochester, N. Y.). These standard suspensions contained from 5.0 x 108 to 1.0 x 109 colonyforming U/ml.
Opsonization procedure. Strains of group B streptococci (types Ia, II, and III) were opsonized by mixing 0.5 ml of the standard solution (OD 0.9 at 620 nm) with 0.1 ml of the test serum (1:6 dilution) in a 12 x 75 mm sterile capped tube (Falcon Plastics, Div. of BioQuest, Oxnard, Calif.). In selected experiments with rabbit hyperimmune serum and in most of the studies with human serum, 0.025 ml of whole human complement (Cordis Laboratories, Miami, Fla.) was added to the reaction mixture. This volume of the preparation was found to maximally enhance the effect of heated rabbit or human serum. Addition of a larger volume had no more effect than 0.025 ml. The phagocytic mixture was then rotated for 30 min at 37°C. After rotation, each tube was centrifuged. The cell button was washed twice in PBS, then resuspended to its original volume (0.5 ml) in PBS.
Preparation of polymorphonuclear leukocytes. Human polymorphonuclear leukocyte (PMN) suspensions were prepared from fresh samples of heparinized (10 U/ml) whole blood obtained from healthy adult volunteers. After sedimentation of the erythrocytes, the leukocyte-rich plasma was removed, centrifuged, and the leukocyte button was washed twice in PBS. The washed leukocytes were suspended in PBS to a concentration of 1.0 x 107 PMNs/ml.
Preparation of precipitin antigen. Hot HCI and TCA extracts of the reference strains of group B streptococci were prepared by slight modifications of the procedures of Lancefield and Freimer (9, 17, 18 (17) and by counterimmunoelectrophoresis (19) . The colonization status of the maternal-cord infants pairs was not determined. Sera were frozen at -20' to -700C and thawed only once before testing. All sera were tested in the presence of a maximally enhancing amount of whole human complement.
RESULTS
Chemiluminescence (CL). The addition of stock strains of group B streptococci, pre-opsonized in homologous type rabbit antiserum, to washed human leukocytes resulted in an increase in CL which was easily measured in the scintillation counter ( Fig. 1) . No increase in CL was noted when unopsonized bacteria were utilized. A small CL peak was noted for type II, whereas higher peaks were seen for types Ia and III. The rabbit antisera used in this experiment were free of complement (no change in the CL elicited after heating at 56°C for 1 h). Addition of whole human complement to the pre-opsonization mixtures accentuated the CL peak for type Ia by 3,500 cpm and for type II by 6,500 cpm. The peak for type III was not increased by the addition of complement.
A recently isolated type III (wild) strain from an infant with group B streptococcal sepsis was next examined to determine the effect of complement on its opsonization. The peak in CL observed when this organism was opsonized in heated type III rabbit antiserum (14.8 x 103 cpm) was not significantly different from that obtained with the same serum and added complement (14.7 x 103 cpm). Moreover, the CL curves observed with the two phagocytic mixtures were essentially identical. No CL peak was noted when either stock or wild strains of group B streptococci were opsonized in the complement preparations alone.
Additional studies were carried out to determine the effects on CL of (a) using buffered, enriched broth which has been reported to enhance group B capsular polysaccharide production (16), (b) using log phase growth organisms rather than 20-h cultures, The use oforganisms grown in the buffered, enriched broth resulted in a higher rather than a lower peak in CL. The peak in CL produced by type III strains grown in this medium and opsonized in homologous type rabbit or human serum was increased by approximately 4,000 cpm (35-50%) over that produced by strains grown in regular Todd-Hewitt broth and opsonized in the same sera. Addition to PMNs of unopsonized bacteria grown in the enriched broth or of such organisms treated with serum lacking type specific antibody did not result in a peak in CL. Moreover, the use of organisms in log phase growth (4 h incubation), which should presumably have more antiphagocytic factors, did not result in a decrease in the CL peak. Wild type III streptococci in log phase growth opsonized in type III rabbit antiserum and complement produced a slightly higher peak in CL (17.5 x 103 cpm) than did 20-h cultures opsonized in the same opsonic mixture (16.0 x 103 cpm).
The number oforganisms presented to the PMNs had a significant effect on the resulting CL. Very low, almost undetectable peaks were obtained with lower numbers of bacteria (2 logs below the usual number of 5 x 108 to 1 x 109). In contrast, a 3-fold higher number of organisms increase the peak in CL by an average of 133%; 5-fold higher by 315%; and 10-fold by 333%. The number 5 x 108 to 1 x 108 organism (OD 0.9 at 620 nm) was selected (somewhat arbitrarily) as a convenient one that produced a significant but not maximum CL response. With Fig. 2 are the results of 104 separate observations of the bacteria-neutrophil preparations plotted by the peak in CL and the presence or absence ofbacteria inside neutrophils as determined by microscope examination. In every case, where the CL peak exceeded 6,500 cpm, the smear showed that the majority of the bacteria were intracellular and that most PMNs had phagocytized. Conversely, phagocytosis was not observed in any of the preparations which had a CL peak of less than 5,500 cpm. There were 12 instances, 11%, in which one could not predict whether phagocytosis had taken place by referring to the CL peak alone. These mixtures had CL peaks between 5,500 and 6,500 cpm and showed only minimal phagocytic uptake. This led us to select 6,500 cpm as the level of CL which indicates the presence of functional opsonic antibodies.
Cross-opsonization and absorption studies. To determine if the group B streptococcal opsonic antibodies measured by the CL procedure were type specific the following experiments were performed: (a) group B streptococci were pre-opsonized with heterologous type rabbit antiserum and tested for their ability to elicit a peak in CL; (b) an aliquot of each type of rabbit antiserum was absorbed with an equal volume of live homologous or heterologous type organisms; these absorbed sera were then used to pre-opsonize type Ia, II, and III organisms; (c) an aliquot of each type of rabbit antiserum was absorbed with an equal volume of homologous type HC1 or TCA extracted antigen. The resulting precipitate was removed by centrifugation and this absorbed serum was used to pre-opsonize both homologous and heterologous type organisms.
The results of several of these experiments are summarized in Table I . CL peaks were observed for each of the three streptococcal types opsonized with homologous type rabbit antiserum. Absorption of the three types of rabbit serum with homologous type HC1 or TCA extracts had varying effects on the opsonic activity as measured by CL. Both HC1 and TCA extracts reduced the CL activity of the type la serum. In contrast, absorption of type II serum with either of these extracts markedly enhanced its CL activity. The opsonic activity of the type III serum was unchanged when absorbed with HCl-extracted antigen, but was somewhat reduced when absorbed with TCA extract. In no instance did homologous absorption with either the HC1 or TCA extract completely remove the opsonic activity of any of the Prevalence of group B streptococcal opsonins in human sera. 11 maternal-cord paired sera were collected and examined by the CL assay for opsonins against the Ia, II, and III reference strains of group B streptococci. The colonization status of these individuals, unfortunately, was not known. As shown in Fig. 4 , none of the maternal-infant sera had significant opsonic activity (.6,500 cpm) against Ia organisms and only 18% of the infants and 27% of the mothers had serum opsonins to type II. In contrast, 73% of the cord sera and 82% of the maternal specimens possessed opsonic activity to group B streptococci of type III. When present, opsonic activity was usually slightly higher in the maternal serum than in the corresponding cord specimen. All sera were tested against the homologous type reference strain, and when available against the infecting or colonizing strain isolated from the patient. (Unfortunately, some of these organisms were lost before initiation of these antibody studies.) 56% of sera from the 18 colonized mothers (whose infants did not become ill) contained opsonins to the homologous type reference strain (Table IV) . Nine infants from these 18 colonized mothers were also colonized. Unfortunately, the organisms isolated from only four of these maternal infant pairs were available for testing. Two ofthe pairs (50%o) contained high levels of opsonins to the offending organism. Seven of the nine colonized infants (78%) had serum opsonins to the homologous type reference strain. In contrast none of the 13 septicemic infants or the 2 septicemic adults from whom organisms were available had serum opsonic activity (CL 2 6,500) to their infecting organism (Tables III and IV) . 3 ofthe 19 diseased infants and one diseased adult did have antibody to the homologous type reference strain. The differences in antibody prevalence between the colonized and diseased patients against their own strain (P c 0.023) or the homologous type reference strain (P c 0.005) was significant by the Fischer Exact test.
DISCUSSION
Type-specific opsonins for group B streptococci have been demonstrated in human adult and newborn infant serum. Maternal opsonic antibody, which appears to reside in the IgG fraction (as determined by indirect immunofluorescence), crosses the placenta and appears in the newborn infant in most instances. Opsonins to type III group B streptococci were present in one-half to three-fourths of sera tested while antibodies to type II and Ta were less common. Opsonins directed toward the colonizing strain or a homologous type reference strain of group B streptococci were often present in the serum of asymptomatic, colonized patients. In contrast, none of 15 diseased patients had serum opsonic activity for their infecting strain and only 4 of 21 (19%) had opsonins to the homologous type reference strain. These data suggest that the lack of type-specific serum opsonins for group B streptococci may be a factor in the development of serious infection with these organisms.
The antigenic determinants responsible for virulence and the production of opsonic antibodies for the different types of group B streptococci are not precisely defined. (18) . Characterization of this determinant, if it exists, and the antibodies directed against it may be of utmost importance in efforts aimed at developing a vaccine for these organisms.
Of interest is the fact that recently isolated "wild" strains of group B streptococci resist opsonization by antibody and complement more than stock strains ofthe same type. The reason for this phenomena is unknown, but may be related to the quantity of antiphagocytic factors being produced. We were unable to confirm, however, that manipulations designed to enhance capsular polysaccharide production, such as the use of buffered enriched medium or log phase growth cultures, resulted in a decrease in phagocytic uptake when specific antibody was present.
The role of complement, both classic and alternative pathways, in the opsonization of group B streptococci also needs further study. We were consistently able to significantly enhance opsonization of types I and II strains with whole human complement, but this preparation had no effect on type III organisms. This was true if stock or wild group B streptococcal strains were used. In addition, type Ta strains incubated in fresh humian serum demonstrated significant amounts of comiiplement on their surface but did not elicit a peak in CL. This suggests that the alternative pathway mav not play a major role in opsonizing these bacteria. Dossett et al. detected opsonins to group B streptococci in whole blood and serum in 1969 (20) . Subsequently Klesius et al. (21) and Mathews et al. (22) reported that serum from humans and experimentally infected baboons contained opsonins directed against types Ta, Tb, Ic, II, and III organisms. Their studies, which were carried out by visually determining phagocytic uptake and the percentage of PMNs ingesting microorganisms, suggested that types Tb, Ic, II, and III streptococci were naturally and nonspecifically opsonized by 95% of human and baboon sera. Absorption of such serum with homologous type whole organisms did not decrease opsonic activity. In contrast our studies and those of Lancefield and co-workers (10, 18) Clearly, the absence of type-specific opsonic activity appears to be one risk factor in the development of systemic infection.
